It is unanimously recognized in the medical community that ischemic necrosis of the femoral head can be caused by hormone administration. It is significantly more common in females than in males. Most of them also suffer from underlying diseases, such as diseases of the respiratory system, renal insufficiency, systemic immune disorders, and so on. In a foreign cross-sectional study, 10-30% of osteonecrosis cases were related to hormone use. In other literature, prospective longitudinal studies have found that osteonecrosis occurs in only 8-10% of patients on hormone therapy. In some diseases, it is difficult to distinguish the effects of corticosteroids on bone from the effects of these underlying diseases. These (underlying diseases) include deficits in mineralization associated with renal failure or hepatic failure and osteoporosis associated with vascular-related diseases such as systemic lupus erythematosus. Hormones associated with osteonecrosis is substantial and detailed evidence is based on the correlation between hormone therapy and osteonecrosis in whooping and rheumatoid diseases. This is consistent with the fact that patients who have undergone organ transplantation and those with Gaucher’s disease have a higher incidence of osteonecrosis. The dose of hormone necessary to cause osteonecrosis is not known. Doses are also expressed as average daily dose, peak dose, cumulative dose and duration. In some foreign studies of the correlation between hormone dose and osteonecrosis, the average daily dose or peak dose appeared to be more correlated with osteonecrosis relative to the cumulative dose or duration of treatment. Higher doses, even when applied for short periods of time, showed a greater risk. Doses of hormones >20 mg per day demonstrated a higher risk of osteonecrosis. The risk of osteonecrosis due to hormones is particularly high in patients who have undergone kidney transplantation. This may be due to the association with reduced mineralization and structural weakness of cancellous bone. A statistical analysis of a group of 22 studies on the correlation between hormones and osteonecrosis revealed a 4.6-fold increase in the rate of osteonecrosis when the average daily dose was increased by 10 mg/day.